TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03283189

Intervention type: OTHER
Intervention: Group discussions
Description: The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.

Intervention type: OTHER
Intervention: Group discussions
Description: The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.

Intervention type: OTHER
Intervention: Group discussions
Description: The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.

Intervention type: OTHER
Intervention: Group discussions
Description: The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.

Intervention type: OTHER
Intervention: Group discussions
Description: The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
Study: NCT02400788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resminostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study: NCT01140360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
Study: NCT03773042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: For induction and maintenance of sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of sedation.
Study: NCT03339661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1_No proph treatment
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2A_Proph treatment and γδ T cell expansion
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2B_Proph treatment and no γδ T cell expansion
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
Study: NCT04458142

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single buccal infiltration
Description: painless technique for palatal anesthesia,single injection,single puncture given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single buccal infiltration
Description: painless technique for palatal anesthesia,single injection,single puncture given
Study: NCT04851951

Intervention type: PROCEDURE
Intervention: one-shot PRP injection
Description: A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
Study: NCT01078831

Intervention type: OTHER
Intervention: Bronchoscopy
Description: Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
Study: NCT02288507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium-90 radioembolization
Description: Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
Study: NCT04083482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continous venovenous hemofiltraion
Description: CVVH
Study: NCT03615183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Single oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: Single oral capsule
Study: NCT02263183

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Palm Olein
Description: Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palm Olein
Description: Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
Study: NCT01632514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 100,000 U of cholecalciferol weekly for 4 weeks
Study: NCT05317520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold vapor
Description: The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated.
Study: NCT03731962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Description: All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary Angiography
Description: All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
Study: NCT00659204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nano-silver gel exposed
Description: SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcohol-based hand gel
Description: Purell gel applied topically to the hands with a limited exposure time of 10 minutes
Study: NCT03290235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
Study: NCT01178775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: use a pedometer for records steps.
Study: NCT03373305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04179383

Intervention type: OTHER
Group type: OTHER
Intervention: Constitution of a biobank
Description: We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'.

Intervention type: OTHER
Group type: OTHER
Intervention: Constitution of a biobank
Description: We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'.
Study: NCT00085735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given orally
Study: NCT02249650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSB-9-W1
Description: Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
Study: NCT02342795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette substitute
Study: NCT00774462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
Study: NCT03922009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
Study: NCT02543567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV 5*10^10 viral particles (vp)
Description: Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV 2*10^10 (vp)
Description: Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV 0.8*10^10 (vp)
Description: Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
Description: MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo 5*10^7 Inf. U.
Description: MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo 5*10^7 Inf. U.
Description: MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
Study: NCT01815307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80mg/m2/day, day 1-28, every 6 weeks
Study: NCT00746252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
Study: NCT01946321

Intervention type: OTHER
Group type: OTHER
Intervention: Post-amputation functional rehabilitation (normal clinical practice)
Study: NCT01020864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/m² i.v. day 1, every 2nd week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 3 i.v. day 1, every 21nd week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
Study: NCT06501404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose group
Description: A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose group
Description: A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
Study: NCT01133587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wait list control
Description: Patient-guided admissions contract regarding patient-guided admissions starting a year after.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: admissions contract
Description: contract regarding patient-guided admissions starting immediately
Study: NCT03535753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and R-GDP
Description: Decitabine and R-GDP
Study: NCT04134962

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment
Description: The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment
Description: The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured.
Study: NCT04824508

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: position
Description: teamleaders are instructed to allocated position

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: position
Description: teamleaders are instructed to allocated position
Study: NCT02266992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Vaccine- Fluenz Tretra
Description: Intra-nasal administration of 0.2ml (0.1ml in each nostril).
Study: NCT01564355

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)
Description: All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)
Description: All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-op Oral Steroids
Description: Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
Study: NCT04192487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer delayed-release tablets 125mg
Description: 1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer delayed-release tablets 125mg
Description: 1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer delayed-release tablets 125mg
Description: 1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
Study: NCT03431155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Description: Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
Study: NCT04042779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: model-based WM training
Description: model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single-task WM training
Description: single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multiple-task WM training
Description: multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: motor training program: four sessions a week, 45 minutes each; lasting for three weeks
Study: NCT02104583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match eleclazine
Description: Placebo to match eleclazine tablets administered orally
Study: NCT04392115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PREPARE program
Description: A home-based exercise program guided by paper materials, weekly phone calls, and a DVD.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility.
Study: NCT04778098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Received SMS reminder
Description: telenursing
Study: NCT04252430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: Single oral dose administration of MD1003 at Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: Single oral dose administration of MD1003 at Day 1
Study: NCT03239574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MightySat
Description: MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
Study: NCT03640923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a swab of mucous membrane
Description: a swab of mucous membrane in oredre to analyse the genome
Study: NCT02913937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Description: Endodontic irrigation followed by passive ultrasonic agitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic needle
Description: Endodontic irrigation
Study: NCT02386488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg single dose
Description: 10 mg tablet for oral use, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg single dose
Description: Two 10 mg tablets for oral use, single dose,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg multiple dose
Description: 10 mg tablet for oral use once, daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg multiple dose
Description: Two 10 mg tablets for oral use, once daily for 14 days.